MCID: DST006
MIFTS: 44

Diastolic Heart Failure

Categories: Cardiovascular diseases

Aliases & Classifications for Diastolic Heart Failure

MalaCards integrated aliases for Diastolic Heart Failure:

Name: Diastolic Heart Failure 12 15 17
Heart Failure, Diastolic 43 71

Classifications:



External Ids:

Disease Ontology 12 DOID:9775
ICD9CM 34 428.3 428.30
MeSH 43 D054144
ICD10 32 I50.30
UMLS 71 C1135196

Summaries for Diastolic Heart Failure

MalaCards based summary : Diastolic Heart Failure, also known as heart failure, diastolic, is related to idiopathic edema and constrictive pericarditis. An important gene associated with Diastolic Heart Failure is ACE (Angiotensin I Converting Enzyme), and among its related pathways/superpathways are Pathways in cancer and cGMP-PKG signaling pathway. The drugs Atorvastatin and Etanercept have been mentioned in the context of this disorder. Affiliated tissues include heart, kidney and brain, and related phenotypes are cardiovascular system and behavior/neurological

Related Diseases for Diastolic Heart Failure

Diseases related to Diastolic Heart Failure via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 238)
# Related Disease Score Top Affiliating Genes
1 idiopathic edema 30.9 NPPB NPPA ACE
2 constrictive pericarditis 30.7 TTN NPPB ACE
3 muscle hypertrophy 30.5 TTN NPPA AGT
4 coronary heart disease 1 30.5 NPPB NOS3 AGTR1 ACE
5 left bundle branch hemiblock 30.4 NPPB MYBPC3 ACE
6 restrictive cardiomyopathy 30.4 TTN NPPB MYBPC3 ACE
7 atrial standstill 1 30.4 TTN NPPB NPPA MYBPC3 ACE
8 hypertension, diastolic 30.3 REN NPPA ACE
9 hypertrophic cardiomyopathy 30.2 TTN MYBPC3 ANKRD1 AGT ACE
10 systolic heart failure 30.2 NPPB NPPA NOS3 MMP9 MMP2 MMP1
11 atherosclerosis susceptibility 30.1 NOS3 MMP9 AGTR1 ACE
12 mitral valve insufficiency 30.1 REN NPPB NPPA MYBPC3 ACE
13 pulmonary edema 30.0 REN NPPB NPPA NOS3 AGTR1 AGT
14 cardiac tamponade 30.0 REN NPPB ACE
15 heart valve disease 30.0 REN NPPB NPPA MIR499A ACE
16 arteriosclerosis 30.0 NOS3 MMP9 CST3 ACE
17 sleep apnea 30.0 REN NPPB NOS3 AGT ACE
18 coronary artery anomaly 30.0 NPPB NPPA NOS3 MMP9 AGTR1 ACE
19 eclampsia 29.6 REN NOS3 AGTR1 AGT ACE
20 central sleep apnea 29.6 REN NPPB NPPA NOS3 ACE
21 congestive heart failure 29.6 TTN REN PDE5A NPPB NPPA NOS3
22 respiratory failure 29.5 TTN REN NPPB NPPA ACE
23 end stage renal failure 29.3 REN NPPB NPPA CST3 AGTR1 AGT
24 autosomal dominant polycystic kidney disease 29.3 REN NOS3 CST3 AGTR1 AGT ACE
25 polycystic kidney disease 29.3 REN NOS3 CST3 AGTR1 AGT ACE
26 arteries, anomalies of 29.3 REN NPPB NOS3 MMP9 AGTR1 AGT
27 cardiac arrest 29.2 TTN REN NPPB MYBPC3 ACE
28 kidney disease 29.2 REN NPPB NPPA NOS3 CST3 CCN2
29 pulmonary hypertension 29.1 REN PDE5A NPPB NPPA NOS3 AGTR1
30 hypertensive heart disease 29.1 REN NPPB NPPA MMP9 MMP2 MMP1
31 chronic kidney disease 29.0 REN NPPB NPPA NOS3 CST3 CCN2
32 renal hypertension 29.0 REN NPPB NOS3 CYBB AGTR1 AGT
33 vascular disease 28.9 REN NPPB NOS3 MMP9 CYBB CST3
34 mitral valve disease 28.8 REN NPPB NPPA NOS3 MMP1 AGTR1
35 atrial fibrillation 28.7 TTN REN NPPB NPPA NOS3 MYBPC3
36 aortic valve disease 2 28.6 TTN REN NPPB NPPA NOS3 MYBPC3
37 stroke, ischemic 28.5 REN NPPB NPPA NOS3 MMP9 CST3
38 diabetes mellitus 27.8 REN PDE5A NPPB NOS3 MMP9 CST3
39 heart disease 27.6 TTN REN PDE5A NPPB NPPA NOS3
40 pre-eclampsia 27.5 REN PDE5A NPPA NOS3 MMP9 MMP2
41 cardiovascular system disease 27.5 REN PDE5A NPPB NPPA NOS3 MIR499A
42 dilated cardiomyopathy 26.9 TTN REN NPPB NPPA NOS3 MYBPC3
43 alzheimer disease 5 10.5 AGTR1 ACE
44 progressive muscular dystrophy 10.5 NPPA CCN2
45 posterior urethral valves 10.5 AGTR1 AGT ACE
46 meningococcal infection 10.5 AGTR1 AGT
47 iga nephropathy 1 10.4 AGTR1 ACE
48 anterolateral myocardial infarction 10.4 NPPB NPPA ACE
49 acute mountain sickness 10.4 NOS3 AGTR1 ACE
50 extracranial arteriovenous malformation 10.4 MMP9 MMP2

Graphical network of the top 20 diseases related to Diastolic Heart Failure:



Diseases related to Diastolic Heart Failure

Symptoms & Phenotypes for Diastolic Heart Failure

MGI Mouse Phenotypes related to Diastolic Heart Failure:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.1 ACE AGT AGTR1 ANKRD1 CCN2 CST3
2 behavior/neurological MP:0005386 10.06 ACE AGT AGTR1 ANKRD1 CYBB MADD
3 homeostasis/metabolism MP:0005376 10.06 ACE AGT AGTR1 ANKRD1 CCN2 CST3
4 muscle MP:0005369 9.7 AGT ANKRD1 CST3 CYBB MMP2 MMP9
5 renal/urinary system MP:0005367 9.23 ACE AGT AGTR1 CYBB MMP9 NOS3

Drugs & Therapeutics for Diastolic Heart Failure

Drugs for Diastolic Heart Failure (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 135)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Atorvastatin Approved Phase 4 134523-00-5 60823
2
Etanercept Approved, Investigational Phase 4 185243-69-0
3
Adalimumab Approved Phase 4 331731-18-1 16219006
4
Infliximab Approved Phase 4 170277-31-3
5
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
6
Furosemide Approved, Vet_approved Phase 4 54-31-9 3440
7
Sodium citrate Approved, Investigational Phase 4 68-04-2
8
Allopurinol Approved Phase 4 315-30-0 2094
9
Nebivolol Approved, Investigational Phase 4 152520-56-4, 118457-14-0, 99200-09-6 71301
10
Empagliflozin Approved Phase 4 864070-44-0
11
Regadenoson Approved, Investigational Phase 4 313348-27-5 219024
12
Adenosine Approved, Investigational Phase 4 58-61-7 60961
13
Valsartan Approved, Investigational Phase 4 137862-53-4 60846
14
Angiotensin II Approved, Investigational Phase 4 68521-88-0, 4474-91-3, 11128-99-7 172198
15
Amlodipine Approved Phase 4 88150-42-9 2162
16
Eplerenone Approved Phase 4 107724-20-9 150310 443872
17
Glucagon Approved Phase 4 16941-32-5
18
Exenatide Approved, Investigational Phase 4 141758-74-9 15991534
19
Ambrisentan Approved, Investigational Phase 4 177036-94-1 6918493
20
Citric acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
21
Calcium Approved, Nutraceutical Phase 4 7440-70-2 271
22
Uric acid Investigational Phase 4 69-93-2 1175
23 Anticholesteremic Agents Phase 4
24 Hypolipidemic Agents Phase 4
25 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 4
26 Lipid Regulating Agents Phase 4
27 Analgesics Phase 4
28 Anti-Inflammatory Agents Phase 4
29 Anti-Inflammatory Agents, Non-Steroidal Phase 4
30 Analgesics, Non-Narcotic Phase 4
31 Gastrointestinal Agents Phase 4
32 Dermatologic Agents Phase 4
33 Immunosuppressive Agents Phase 4
34 Antimetabolites Phase 4
35 Sympathomimetics Phase 4
36 Dopamine Agents Phase 4
37 Sodium Potassium Chloride Symporter Inhibitors Phase 4
38 Hypoglycemic Agents Phase 4
39 Citrate Phase 4
40 Phosphodiesterase Inhibitors Phase 4
41 Sildenafil Citrate Phase 4 171599-83-0
42 Phosphodiesterase 5 Inhibitors Phase 4
43 Free Radical Scavengers Phase 4
44 2-(3-(4-ethoxybenzyl)-4-chlorophenyl)-6-hydroxymethyltetrahydro-2H-pyran-3,4,... Phase 4
45 Neurotransmitter Agents Phase 4
46 Adrenergic beta-Agonists Phase 4
47 LCZ 696 Phase 4
48 Vasodilator Agents Phase 4
49 Calcium, Dietary Phase 4
50 calcium channel blockers Phase 4

Interventional clinical trials:

(show top 50) (show all 164)
# Name Status NCT ID Phase Drugs
1 Prospective Evaluation of Heart Function by Echocardiographic Study, Pro-brain Natriuretic Peptide Type B and Troponin T in Patients With Rheumatoid Arthritis and Ankylosing Spondylitis Pre and Post-TNF Blocker Unknown status NCT01072058 Phase 4 TNF blockers (infliximab, adalimumab, etanercept)
2 Effects of Atorvastatin Treatment on Left Ventricular Diastolic Function in Peritoneal Dialysis Patients (ALEVENT) Unknown status NCT01503671 Phase 4 Atorvastatin
3 A Double-blind, Randomised, Placebo-controlled, Parallel Group Study to Determine the Effects of Valsartan on Exercise Time in Subjects With Symptomatic Diastolic Heart Failure Completed NCT00171106 Phase 4 valsartan
4 Novel Treatment for Diastolic Heart Failure in Women Completed NCT00206232 Phase 4 Spironolactone
5 Aldosterone Antagonism in Diastolic Heart Failure Completed NCT00108251 Phase 4 Eplerenone;Placebo
6 Randomized Evaluation of Heart Failure With Preserved Ejection Fraction (HFpEF) Patients With Acute Heart Failure and Dopamine (ROPA-DOP) Trial Completed NCT01901809 Phase 4 Furosemide;Dopamine
7 Impacts of Aldosterone Blockade on Myocardial Remodeling in Hypertensive Patients With Diastolic Failing Heart Completed NCT01944384 Phase 4 aldactone
8 SIDAMI - Sildenafil and Diastolic Dysfunction After AMI Completed NCT01046838 Phase 4 Sildenafil;Placebo
9 Effects of Allopurinol on Diastolic Function in Chronic Heart Failure Patients Completed NCT00477789 Phase 4 allopurinol
10 Fimasartan for Improvement of Diastolic Dysfunction in Hypertensive Patients Completed NCT01691118 Phase 4 Fimasartan;Antihypertensive treatment
11 DAPA-LVH - Does Dapagliflozin Regress Left Ventricular Hypertrophy In Patients With Type 2 Diabetes? Completed NCT02956811 Phase 4 Dapagliflozin;Placebo
12 Improving Treatment Personalization of Pulmonary Hypertension Associated With Diastolic Heart Failure Recruiting NCT02053246 Phase 4 Nebivolol
13 Respiratory Muscle-mediated Neural and Cardiovascular Consequences in Heart Failure With Preserved Ejection Fraction Recruiting NCT03924479 Phase 4
14 A Phase 4, Single-center, Randomized, Parallel Group Study to Assess Effects of Empagliflozin on Exercise Capacity and Left Ventricular Diastolic Function in Patients With Heart Failure With Preserved Ejection Fraction and Type-2 Diabetes Mellitus Recruiting NCT03753087 Phase 4 Empagliflozin
15 Myocardial Perfusion, Oxidative Metabolism, and Fibrosis in HFpEF Recruiting NCT02589977 Phase 4 regadenoson
16 A Proof of Concept Study to Determine the Efficacy of Entresto™ in HFpEF Based on Circulating Neprilysin Levels: The Circulating NEP and NEP Inhibition (CNEPi) Study Recruiting NCT03506412 Phase 4 Entresto™ 49Mg-51 mg tablet
17 Effect of Add-on of Amlodipine Versus Valsartan on Diastolic Dysfunction Associated With Hypertension Active, not recruiting NCT02973035 Phase 4 Amlodipine;Valsartan
18 A Phase 4, Randomized, Open Label, Multicenter Prospective Comparative Study To Evaluate The Treatment Of Atrial Fibrillation In Preserved Cardiac Function Heart Failure Not yet recruiting NCT04160000 Phase 4 Rate or Rhythm control antiarrhythmic drugs for atrial fibrillation
19 The EMMED-HF Study: Evaluating Metabolic Mechanisms of Ertugliflozin in Diabetes & Heart Failure Not yet recruiting NCT04071626 Phase 4 Ertugliflozin 5 mg;Placebo oral tablet
20 Determine the Effectiveness of Eplerenone in Reversing Diastolic Dysfunction, Improving Endothelial Function, and Suppressing Natriuretic Peptides and Collagen Turnover in Patients With Diastolic Heart Failure ( PREDICT Study) Terminated NCT00293150 Phase 4 Eplerenone
21 Treatment With Glucagon-Like Peptide-1 Receptor, Exenatide, in Patients With Diabetes and Heart Failure With Normal Left Ventricular Ejection Fraction Terminated NCT00799435 Phase 4 Exenatide
22 The Use of Nesiritide in the Management of Acute Diastolic Heart Failure Terminated NCT00083772 Phase 4 Nesiritide
23 Safety and Efficacy Trial Using Ambrisentan for Pulmonary Hypertension Associated With Congestive Heart Failure With Preserved Left Ventricular Ejection Fraction Terminated NCT00840463 Phase 4 Ambrisentan
24 Sympathetic Renal Denervation in Heart Failure With Normal LV Ejection Fraction: Denervation of the renAl sympathetIc nerveS in hearT Failure With nOrmal Lv Ejection Fraction Unknown status NCT01583881 Phase 2, Phase 3
25 Udenafil Therapy to Improve Symptomatology, Exercise Tolerance and Hemodynamics in Patients With Heart Failure With Preserved Ejection Fraction: Phase III, Randomized, Double-blind, Placebo-controlled Trial [ULTIMATE-HFpEF Trial] Unknown status NCT01599117 Phase 3 Placebo;Udenafil (Zydena)
26 Exercise Intolerance in Elderly Diastolic Heart Failure Completed NCT00123955 Phase 3 Spironolactone;Placebo
27 Evaluation of Enalapril Versus Placebo in Patients With Diastolic Heart Failure Completed NCT01411735 Phase 3 Enalapril;placebo
28 Phosphodiesterase-5 Inhibition to Improve Clinical Status and Exercise Capacity in Diastolic Heart Failure (RELAX) Completed NCT00763867 Phase 3 Placebo;Sildenafil
29 Effects of Sildenafil on Pulmonary Arterial Pressure in Patients With Heart Failure With Preserved Ejection Fraction ( HFpEF) and Pulmonary Hypertension Completed NCT01726049 Phase 3 Sildenafil;Placebo
30 Pulmonary Hypertension Secondary to Heart Failure With Preserved Systolic Function: a Target of Phosphodiesterase - 5 Inhibition in a 1- Year Duration Study Completed NCT01156636 Phase 2, Phase 3 Sildenafil;Placebo
31 Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) Completed NCT00094302 Phase 3 Spironolactone;Placebo
32 A Multicenter, Randomized, Double-blind, Parallel Group, Active-controlled Study to Evaluate the Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients (NYHA Class II-IV) With Preserved Ejection Fraction Completed NCT01920711 Phase 3 LCZ696;Valsartan
33 Aldosterone-blockade Randomized Controlled Trial In CHF - Diastolic Completed NCT00523757 Phase 3 Spironolactone;Placebo
34 Endothelin Receptor Blockade in Heart Failure With Diastolic Dysfunction and Pulmonary Hypertension Completed NCT00820352 Phase 3 bosentan;placebo
35 Candesartan "Added" Therapy for Treatment Optimization of Symptomatic Heart Failure With Diastolic Dysfunction in Diabetic and Hypertensive Patients A Randomized, Placebo-controlled, Double-blind, Parallel-group and Multicenter Clinical Phase III Study Investigating the Effects on NT-proBNP Over 6 Months Completed NCT00775840 Phase 3 Candesartan;Placebo
36 MB001-067 A PROSPECTIVE, DOUBLE BLIND, PLACEBO CONTROLLED, PARALLEL GROUP, RANDOMIZED TRIAL OF EXTENDED RELEASE EXENATIDE VERSUS PLACEBO (COHORT A) AND A PROSPECTIVE, SINGLE GROUP, OPEN-LABEL, BLINDED OUTCOME TRIAL OF EXTENDED RELEASE EXENATIDE (COHORT B) IN DIABETIC PATIENTS WITH TYPE 4 CARDIORENAL SYNDROME (EXTEND-CRS TRIAL) AMENDMENT 3 Recruiting NCT02251431 Phase 3 BYDUREON;Placebo
37 Optimized Management of Comorbidity in Heart Failure With Preserved Ejection Fraction in the Elderly (>60 Years) (OPTIMIZE-HFPEF) Recruiting NCT02425371 Phase 3
38 A Prospective Randomized Placebo-controlled Study of the Effect of Eplerenone on Left Ventricular Diastolic Function in Women Receiving Anthracycline Therapy for Breast Cancer Terminated NCT01708798 Phase 2, Phase 3 Eplerenone;Placebo
39 A Pilot Study Of ALT-711 In Elderly Patients With Isolated Diastolic Heart Failure: The DIAMOND Study Completed NCT00043836 Phase 2 ALT-711
40 A Study of the Acute Hemodynamic and Myocardial Effects of Nesiritide in Diastolic Heart Failure. Completed NCT00309868 Phase 1, Phase 2 neseritide
41 Evaluation of Efficacy and Safety of Metoprolol XR in Patients Having Heart Failure With Normal Ejection Fraction: A Randomised, Double Blind,Placebo Controlled Trial Completed NCT03882710 Phase 2 Metoprolol XR
42 A Phase 2 Randomised, Double-Blind, Placebo-Controlled Exploratory Efficacy Study Of Sitaxsentan Sodium To Improve Impaired Exercise Tolerance In Subjects With Diastolic Heart Failure Completed NCT00303498 Phase 2 Sitaxsentan sodium;Placebo
43 A Randomized, Double-blind, Placebo-controlled Study of Ranolazine in Patients With Heart Failure With Preserved Ejection Fraction Completed NCT01163734 Phase 2 Ranolazine
44 Randomised Double Blind Placebo Controlled Trial of Perhexiline in Heart Failure With Preserved Ejection Fraction Syndrome (HFpEF) Completed NCT00839228 Phase 2 Perhexiline;Placebo
45 To Define in Normal Controls, Human Preclinical Systolic Dysfunction (PSD) and Preclinical Diastolic Dysfunction (PDD) the Actions of Acute Subcutaneous Nesiritide (BNP) on the Cardiorenal and Humoral Function and the Integrated Response to Acute Sodium Loading Completed NCT00387621 Phase 1, Phase 2 Nesiritide;Placebo;Saline
46 Radiofrequency-based Speckle Tracking Echocardiography to Evaluate Diastolic Function Completed NCT01182805 Phase 1, Phase 2
47 Pharmacokinetics, Pharmacodynamics, and Impact of Inorganic Nitrate on Exercise in HFpEF Completed NCT02256345 Phase 2 KNO3;KCl
48 A Dose Escalation Study to Evaluate the Effect of Inhaled Nitrite on Cardiopulmonary Hemodynamics in Subjects With Pulmonary Hypertension Completed NCT01431313 Phase 2 Inhaled Nitrite
49 Interleukin-1 Blockade in Heart Failure With Preserved Ejection Fraction (HFpEF): a Randomized Placebo-controlled Double Blinded Study (D-HART2) Completed NCT02173548 Phase 2 Anakinra;Placebo
50 Reducing Symptom Burden in Patients With Heart Failure With Preserved Ejection Fraction Using Ubiquinol and/or D-ribose Recruiting NCT03133793 Phase 2 CoQ10;D-Ribose Oral Powder

Search NIH Clinical Center for Diastolic Heart Failure

Cochrane evidence based reviews: heart failure, diastolic

Genetic Tests for Diastolic Heart Failure

Anatomical Context for Diastolic Heart Failure

MalaCards organs/tissues related to Diastolic Heart Failure:

40
Heart, Kidney, Brain, Testes, Lung, Endothelial, Breast

Publications for Diastolic Heart Failure

Articles related to Diastolic Heart Failure:

(show top 50) (show all 1219)
# Title Authors PMID Year
1
Diagnostic and prognostic value of serum C-reactive protein in heart failure with preserved ejection fraction: a systematic review and meta-analysis. 61
32030562 2020
2
Left atrial dysfunction in sickle cell anemia is associated with diffuse myocardial fibrosis, increased right ventricular pressure and reduced exercise capacity. 61
32019991 2020
3
Gut Microbiome of a Porcine Model of Metabolic Syndrome and HF-pEF. 61
32031871 2020
4
Diastolic Heart Failure in Patients With the Fontan Circulation: A Review. 61
32022823 2020
5
Diagnostic and prognostic value of autoantibodies against β1-adrenoreceptors in patients with heart failure following acute myocardial infarction: A 5-year prospective study. 61
32010297 2020
6
The quintessential form of diastolic heart failure in older adults: Wild type transthyretin cardiac amyloidosis. 61
31825134 2019
7
Left Ventricular Diastolic Dysfunction and Diastolic Heart Failure in Preterm Infants. 61
31598743 2019
8
Sickle cell disease: at the crossroads of pulmonary hypertension and diastolic heart failure. 61
31822569 2019
9
HOSPITAL Score, LACE Index and LACE+ Index as predictors of 30-day readmission in patients with heart failure. 61
31771947 2019
10
Thyroid and Heart: Severe Three Vessel Coronary Artery Disease in a Middle-Aged Female with Hypothyroidism. 61
31857927 2019
11
[Clinical classification and characteristics of alcoholic myocardial injury]. 61
31694119 2019
12
The prevalence and predictors of resistant hypertension in high-risk overweight and obese patients: A cross-sectional study based on the 2017 ACC/AHA guidelines. 61
31448866 2019
13
Plasma receptor tyrosine kinase RET in pulmonary arterial hypertension diagnosis and differentiation. 61
31754623 2019
14
Risk assessment of post-discharge mortality among recently hospitalized Medicare heart failure patients with reduced or preserved ejection fraction. 61
31469001 2019
15
Is echocardiography mandatory for patients with chronic kidney disease? 61
30912000 2019
16
[Heart failure with preserved left ventricular ejection fraction]. 61
31432196 2019
17
Differentiating Constriction from Restriction (from the Mayo Clinic Echocardiographic Criteria). 61
31353007 2019
18
Echocardiographic Diastolic Stress Testing: What Does It Add? 61
31377869 2019
19
Motivational interviewing can support physical activity in elderly patients with diastolic heart failure: results from a pilot study. 61
30963721 2019
20
HIV Infection Is Associated with Greater Left Ventricular Mass in the Multicenter AIDS Cohort Study. 61
31044604 2019
21
[Myocardial Strain Properties in Patients with Chronic Heart Failure]. 61
31397234 2019
22
Alterations on a key nephrogenic/cardiogenic gene expression linked to hypertension development. 61
31472952 2019
23
Identifying a low-flow phenotype in heart failure with preserved ejection fraction: a secondary analysis of the RELAX trial. 61
30993916 2019
24
HAND1 loss-of-function within the embryonic myocardium reveals survivable congenital cardiac defects and adult heart failure. 61
31286141 2019
25
An Approximation of Heart Failure Using Cardiovascular Simulation Toolbox. 61
31295796 2019
26
Emotional intelligence and systolic blood pressure are determinants of cognitive deficits in patients with heart failure. 61
31983738 2019
27
The effect of perindopril on echocardiographic parameters, NYHA functional class and serum NT-proBNP values in patients with diastolic heart failure. 61
31140540 2019
28
Morbidity and mortality in patients with cardiovascular risk factors and obstructive sleep apnoea: results from the DIAST-CHF cohort. 61
31252205 2019
29
Accuracy of Administrative Coding to Identify Reduced and Preserved Left Ventricular Ejection Fraction. 61
30743043 2019
30
Adeno-associated virus 9-mediated RNA interference targeting SOCS3 alleviates diastolic heart failure in rats. 61
30763670 2019
31
[Heart failure with preserved ejection fraction (diastolic heart failure)]. 61
31079412 2019
32
[Aortic Intramural Hematoma: a Challenging Diagnosis]. 61
30925605 2019
33
Board examination stress effect on diastolic function. 61
30421527 2019
34
Urinary Peptidomic Biomarker for Personalized Prevention and Treatment of Diastolic Left Ventricular Dysfunction. 61
30632674 2019
35
Epicardial adipose tissue and cardiovascular diseases. 61
30297191 2019
36
Electropharmacological effects of intracellular Ca2+ handling modulator caldaret on the heart assessed in the halothane-anesthetized dogs. 61
30738725 2019
37
Pericardial calcification: A case report of a three-dimensional disease. 61
30959364 2019
38
Gene Transfer of Calcium-Binding Proteins into Adult Cardiac Myocytes. 61
30710274 2019
39
Acute kidney injury on chronic kidney disease: from congestive heart failure to light chain deposition disease and cast nephropathy in multiple myeloma. 61
31531214 2019
40
Circulating Connective Tissue Growth Factor Is Associated with Diastolic Dysfunction in Patients with Diastolic Heart Failure. 61
31466059 2019
41
Novel paradigms in the therapeutic management of heart failure with preserved ejection fraction: clinical perspectives. 61
31763061 2019
42
Use of a Mechanical Circulatory Support Simulation to Study Pump Interactions With the Variable Hemodynamic Environment. 61
30393881 2018
43
Neutrophil-Initiated Myocardial Inflammation and Its Modulation by B-Type Natriuretic Peptide: A Potential Therapeutic Target. 61
30602672 2018
44
Contractile Function of Isolated Hearts With Preserved and Reduced Ejection Fraction In Vivo. 61
30704381 2018
45
Prediabetes: Why Should We Care? 61
30788015 2018
46
[InterAtrial Shunt Device in diastolic heart failure]. 61
30194481 2018
47
The level of NT-proBNP in ambulatory patients with chronic heart failure with preserved ejection fraction of the left ventricle. 61
30701738 2018
48
Non-ischemic Cardiomyopathy Secondary to Left Ventricular Hypertrophy due to Long-term Anabolic-androgenic Steroid Use in a Former Olympic Athlete. 61
30473946 2018
49
Impact of end stage renal disease on in-hospital outcomes of patients with systolic and diastolic heart failure (insights from the Nationwide Inpatient Sample 2010 to 2014). 61
29887443 2018
50
Light Chain Amyloidosis Presenting as Bilateral External Auditory Canal Obstructing Masses. 61
29957672 2018

Variations for Diastolic Heart Failure

Expression for Diastolic Heart Failure

Search GEO for disease gene expression data for Diastolic Heart Failure.

Pathways for Diastolic Heart Failure

Pathways related to Diastolic Heart Failure according to GeneCards Suite gene sharing:

(show all 20)
# Super pathways Score Top Affiliating Genes
1 12.7 MMP9 MMP2 MMP1 AGTR1 AGT
2
Show member pathways
12.34 PDE5A NPPB NPPA NOS3 AGTR1 AGT
3
Show member pathways
12.33 NPPB NPPA NOS3 AGTR1 AGT
4
Show member pathways
12.08 TTN MYBPC3 AGT ACE
5
Show member pathways
11.76 MMP9 MMP2 MMP1
6 11.65 REN NOS3 MMP9 MMP2
7 11.65 NOS3 MMP2 CYBB AGTR1 AGT
8 11.61 MMP9 MMP2 MMP1
9 11.55 NOS3 MMP9 MMP2
10
Show member pathways
11.52 MMP9 MMP2 MMP1
11 11.51 MMP9 MMP2 CCN2
12 11.49 MMP9 MMP2 MMP1
13
Show member pathways
11.46 REN NOS3 AGTR1 AGT ACE
14 11.35 MMP9 MMP2 CCN2
15 11.15 NOS3 MMP9 MMP2 MMP1
16 11.14 MMP9 MMP2 ACE
17 11.02 NOS3 MMP9 MMP2
18 10.86 REN NPPA AGTR1 AGT ACE
19 10.7 PDE5A NOS3
20 10.62 MMP9 MMP2 CST3 ACE

GO Terms for Diastolic Heart Failure

Cellular components related to Diastolic Heart Failure according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular matrix GO:0031012 9.62 MMP9 MMP2 MMP1 CCN2
2 extracellular space GO:0005615 9.61 REN NPPB NPPA MMP9 MMP2 CST3
3 collagen-containing extracellular matrix GO:0062023 9.55 NPPA MMP9 MMP2 CCN2 AGT
4 sarcomere GO:0030017 9.43 TTN MYBPC3 MMP2
5 extracellular region GO:0005576 9.36 TTN REN NPPB NPPA MMP9 MMP2

Biological processes related to Diastolic Heart Failure according to GeneCards Suite gene sharing:

(show all 28)
# Name GO ID Score Top Affiliating Genes
1 cellular protein metabolic process GO:0044267 9.87 NPPA MMP2 MMP1 CST3
2 cellular response to mechanical stimulus GO:0071260 9.76 NPPA ANKRD1 AGT
3 kidney development GO:0001822 9.73 REN AGTR1 AGT ACE
4 extracellular matrix disassembly GO:0022617 9.72 MMP9 MMP2 MMP1
5 collagen catabolic process GO:0030574 9.7 MMP9 MMP2 MMP1
6 response to amyloid-beta GO:1904645 9.64 MMP9 MMP2
7 amyloid-beta metabolic process GO:0050435 9.63 REN ACE
8 cardiac muscle tissue morphogenesis GO:0055008 9.63 TTN ANKRD1
9 blood vessel remodeling GO:0001974 9.63 NOS3 AGT ACE
10 positive regulation of renal sodium excretion GO:0035815 9.62 NPPB AGT
11 low-density lipoprotein particle remodeling GO:0034374 9.62 AGTR1 AGT
12 positive regulation of vascular smooth muscle cell proliferation GO:1904707 9.62 MMP9 MMP2 MIR499A AGT
13 negative regulation of systemic arterial blood pressure GO:0003085 9.61 NPPB NPPA
14 angiotensin maturation GO:0002003 9.61 REN ACE
15 positive regulation of cardiac muscle contraction GO:0060452 9.6 NPPA CCN2
16 cGMP biosynthetic process GO:0006182 9.59 NPPB NPPA
17 receptor guanylyl cyclase signaling pathway GO:0007168 9.58 NPPB NPPA
18 positive regulation of cholesterol esterification GO:0010873 9.56 AGTR1 AGT
19 positive regulation of NAD(P)H oxidase activity GO:0033864 9.54 AGTR1 AGT
20 regulation of vasoconstriction GO:0019229 9.54 AGTR1 AGT ACE
21 regulation of renal sodium excretion GO:0035813 9.51 AGTR1 AGT
22 regulation of blood vessel diameter by renin-angiotensin GO:0002034 9.49 AGTR1 AGT
23 regulation of blood volume by renin-angiotensin GO:0002016 9.48 REN AGT
24 regulation of systemic arterial blood pressure by renin-angiotensin GO:0003081 9.43 AGTR1 AGT ACE
25 regulation of renal output by angiotensin GO:0002019 9.4 AGT ACE
26 renin-angiotensin regulation of aldosterone production GO:0002018 9.33 REN AGTR1 AGT
27 regulation of blood vessel diameter GO:0097746 9.26 NPPB NOS3 AGTR1 ACE
28 regulation of blood pressure GO:0008217 9.1 REN NPPB NPPA NOS3 AGT ACE

Molecular functions related to Diastolic Heart Failure according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 peptidase activity GO:0008233 9.72 REN MMP9 MMP2 MMP1 ACE
2 metalloendopeptidase activity GO:0004222 9.58 MMP9 MMP2 MMP1
3 metallopeptidase activity GO:0008237 9.56 MMP9 MMP2 MMP1 ACE
4 titin binding GO:0031432 9.37 MYBPC3 ANKRD1
5 hormone receptor binding GO:0051427 9.16 NPPB NPPA
6 bradykinin receptor binding GO:0031711 8.96 AGTR1 ACE
7 endopeptidase activity GO:0004175 8.92 REN MMP9 MMP1 ACE

Sources for Diastolic Heart Failure

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....